Puma Biotechnology Inc (NASDAQ:PBYI)
| 4.11 Delayed Data As of Dec 08 |  -0.07 / -1.67%Today’s Change | 2.13 Today|||52-Week Range 5.16 | -2.84% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $196.0M |
Company Description
Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
Contact Information
Puma Biotechnology, Inc. 10880 Wilshire Boulevard Los Angeles California 90024-4101 |
Employees
Shareholders
| Other institutional | 41.54% |
| Individual stakeholders | 27.00% |
| Mutual fund holders | 12.61% |
Top Executives
| Alan H. Auerbach | Chairman, President, CEO & Secretary |
| Maximo F. Nougues | Chief Financial & Accounting Officer |
| Alvin F. Wong | Chief Scientific Officer |
| Jeffrey Ludwig | Chief Commercial Officer |
| Mariann Ohanesian | Senior Director-Investor Relations |
